• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫应激诱导的4T1乳腺癌细胞肿瘤突变负荷和新抗原表达:免疫检查点抑制剂治疗患者长期生存的潜在机制

Immune Stress-induced Tumor Mutation Burden and Neoantigen Expression in 4T1 Mammary Cancer Cells: A Potential Mechanism for Long-term Survival in Patients Treated With Immune Checkpoint Inhibitors.

作者信息

Ishiguro Tomoyuki, Takeda Kazuyuki, Takayanagi Daisuke, Mura Emiko, Suzuki Risako, Tsurui Toshiaki, Iriguchi Nana, Hirasawa Yuya, Ohkuma Ryotaro, Shimokawa Masahiro, Ariizumi Hirotsugu, Kubota Yutaro, Horiike Atsushi, Izumizaki Masahiko, Wada Satoshi, Yoshimura Kiyoshi, Hoffman Robert M, Tsunoda Takuya

机构信息

Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.

Laboratory of Cell Biology, Biomedical Research Core Facilities, Graduate School of Medicine, Juntendo University, Tokyo, Japan.

出版信息

Cancer Genomics Proteomics. 2025 Jan-Feb;22(1):1-12. doi: 10.21873/cgp.20481.

DOI:10.21873/cgp.20481
PMID:39730175
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11696327/
Abstract

BACKGROUND/AIM: The Kaplan-Meier curves for patients treated with immune checkpoint inhibitors (ICIs) display a small group of potentially-cured patients with long-term survival, creating a 'kangaroo-tail' shape of the survival curve. However, the mechanistic basis of this phenomenon and what occurs in patients whose cancer is resistant to ICIs remain unclear. The present study aimed to answer these questions.

MATERIALS AND METHODS

We analyzed mutations in mouse 4T1 mammary-gland-derived cancer cells expressing the hemagglutinin antigen (4T1-HA), which were grown in either wild-type mice or cytotoxic T-lymphocyte (CTL)-loaded immunocompromised mice (RAG-/- + ACT) under immune stress. These mutations were compared to those in 4T1-HA cells grown in RAG-/- mice without immune stress as a control.

RESULTS

The number of gene mutations, the tumor mutation burden (TMB) and microsatellite instability (MSI) scores were increased in the cancer cells under immune stress. The mutations in the antigen protein were such that the protein retained its immunogenicity and could still function as a neoantigen. Repeated immune recognition of additional neoantigens may lead to the kangaroo-tail survival phenomenon. The common genetic mutations of the analyzed 4T1-HA cells under immune stress included genes related to immune response. Analysis of alternative splicing of genes showed that are accumulated gene alterations under immune stress related to cancer-cell proliferation. Copy-number variation (CNV) analysis indicated that normal-antigen presentation and immune responses may be impaired under immune stress.

CONCLUSION

Cancer cells, under immune stress, may acquire both immune escape capabilities and increased immunogenicity. This dual effect could lead to either resistance or response to ICIs, respectively.

摘要

背景/目的:接受免疫检查点抑制剂(ICI)治疗的患者的Kaplan-Meier曲线显示,一小部分患者有可能被治愈并长期存活,从而使生存曲线呈现出“袋鼠尾”的形状。然而,这一现象的机制基础以及癌症对ICI耐药的患者体内发生了什么仍不清楚。本研究旨在回答这些问题。

材料与方法

我们分析了表达血凝素抗原的小鼠4T1乳腺来源癌细胞(4T1-HA)中的突变,这些细胞在野生型小鼠或负载细胞毒性T淋巴细胞(CTL)的免疫缺陷小鼠(RAG-/- + ACT)中于免疫应激条件下生长。将这些突变与在无免疫应激的RAG-/-小鼠中生长的4T1-HA细胞中的突变进行比较,作为对照。

结果

在免疫应激条件下,癌细胞中的基因突变数量、肿瘤突变负荷(TMB)和微卫星不稳定性(MSI)评分均增加。抗原蛋白中的突变使得该蛋白保留了其免疫原性,并且仍然可以作为新抗原发挥作用。对其他新抗原的反复免疫识别可能导致袋鼠尾生存现象。在免疫应激条件下分析的4T1-HA细胞的常见基因突变包括与免疫反应相关的基因。对基因可变剪接的分析表明,在免疫应激条件下积累的基因改变与癌细胞增殖有关。拷贝数变异(CNV)分析表明,在免疫应激条件下,正常抗原呈递和免疫反应可能受损。

结论

在免疫应激条件下,癌细胞可能同时获得免疫逃逸能力和增强的免疫原性。这种双重效应可能分别导致对ICI的耐药或反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3050/11696327/18340abe0195/cgp-22-10-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3050/11696327/c6b170c7d6c1/cgp-22-2-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3050/11696327/521996cd9b36/cgp-22-4-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3050/11696327/35058cab6fd1/cgp-22-5-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3050/11696327/ac5775f9b486/cgp-22-6-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3050/11696327/cf4709c7e8e0/cgp-22-7-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3050/11696327/08c921cb6e48/cgp-22-8-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3050/11696327/18340abe0195/cgp-22-10-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3050/11696327/c6b170c7d6c1/cgp-22-2-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3050/11696327/521996cd9b36/cgp-22-4-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3050/11696327/35058cab6fd1/cgp-22-5-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3050/11696327/ac5775f9b486/cgp-22-6-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3050/11696327/cf4709c7e8e0/cgp-22-7-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3050/11696327/08c921cb6e48/cgp-22-8-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3050/11696327/18340abe0195/cgp-22-10-g0001.jpg

相似文献

1
Immune Stress-induced Tumor Mutation Burden and Neoantigen Expression in 4T1 Mammary Cancer Cells: A Potential Mechanism for Long-term Survival in Patients Treated With Immune Checkpoint Inhibitors.免疫应激诱导的4T1乳腺癌细胞肿瘤突变负荷和新抗原表达:免疫检查点抑制剂治疗患者长期生存的潜在机制
Cancer Genomics Proteomics. 2025 Jan-Feb;22(1):1-12. doi: 10.21873/cgp.20481.
2
RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.RB1 和 TP53 共突变与膀胱癌对免疫检查点抑制剂反应的基因组生物标志物密切相关。
BMC Cancer. 2021 Apr 20;21(1):432. doi: 10.1186/s12885-021-08078-y.
3
ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.ZFHX3 突变作为非小细胞肺癌免疫检查点阻断的保护性生物标志物。
Cancer Immunol Immunother. 2021 Jan;70(1):137-151. doi: 10.1007/s00262-020-02668-8. Epub 2020 Jul 11.
4
ARID1A-Deficient Tumors Acquire Immunogenic Neoantigens during the Development of Resistance to Targeted Therapy.ARID1A 缺陷型肿瘤在对靶向治疗产生耐药性的过程中获得免疫原性新抗原。
Cancer Res. 2024 Sep 4;84(17):2792-2805. doi: 10.1158/0008-5472.CAN-23-2846.
5
Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.MUC16 突变与实体瘤免疫检查点抑制剂反应的关联。
JAMA Netw Open. 2020 Aug 3;3(8):e2013201. doi: 10.1001/jamanetworkopen.2020.13201.
6
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.综合基因组分析、肿瘤突变负担和 PD-L1 表达的整合,以鉴定非小细胞肺癌免疫治疗的新型生物标志物。
Cancer Med. 2021 Apr;10(7):2216-2231. doi: 10.1002/cam4.3649. Epub 2021 Mar 2.
7
Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner.新出现的已建立肿瘤中的免疫原性新生抗原使宿主能够以 T 细胞依赖的方式重新获得免疫监视。
Int Immunol. 2021 Jan 1;33(1):39-48. doi: 10.1093/intimm/dxaa049.
8
Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation.优化的多表位新抗原 DNA 疫苗在临床前模型和临床转化中引发新抗原特异性免疫反应。
Genome Med. 2021 Apr 21;13(1):56. doi: 10.1186/s13073-021-00872-4.
9
Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.TP53 改变可能成为膀胱癌患者接受免疫检查点抑制治疗获益的潜在生物标志物。
Cancer Control. 2020 Jan-Dec;27(1):1073274820976665. doi: 10.1177/1073274820976665.
10
The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.PAK7 突变对非小细胞癌免疫检查点抑制剂治疗的预测价值。
Front Immunol. 2022 Feb 3;13:834142. doi: 10.3389/fimmu.2022.834142. eCollection 2022.

本文引用的文献

1
Calreticulin-Multifunctional Chaperone in Immunogenic Cell Death: Potential Significance as a Prognostic Biomarker in Ovarian Cancer Patients.钙网织蛋白——免疫原性细胞死亡中的多功能伴侣:作为卵巢癌患者预后生物标志物的潜在意义。
Cells. 2021 Jan 11;10(1):130. doi: 10.3390/cells10010130.
2
Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death.癌症联合治疗的当前方法:免疫原性细胞死亡的作用。
Cancers (Basel). 2020 Apr 23;12(4):1047. doi: 10.3390/cancers12041047.
3
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
帕博利珠单抗治疗非结直肠癌高度微卫星不稳定/错配修复缺陷型癌症患者的疗效:来自 II 期 KEYNOTE-158 研究的结果。
J Clin Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4.
4
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.帕博利珠单抗单药或联合化疗对比西妥昔单抗联合化疗用于治疗复发性或转移性头颈部鳞状细胞癌(KEYNOTE-048):一项随机、开放标签、III 期研究。
Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1.
5
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.纳武利尤单抗对比化疗用于既往化疗后进展或不耐受的晚期食管鳞癌患者(ATTRACTION-3):一项多中心、随机、开放标签、III 期临床研究。
Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30.
6
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.纳武利尤单抗联合伊匹单抗治疗晚期非小细胞肺癌。
N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.
7
PIRD: Pan Immune Repertoire Database.PIRD:全免疫受体数据库。
Bioinformatics. 2020 Feb 1;36(3):897-903. doi: 10.1093/bioinformatics/btz614.
8
Strelka2: fast and accurate calling of germline and somatic variants.Strelka2:快速准确地调用种系和体细胞变异。
Nat Methods. 2018 Aug;15(8):591-594. doi: 10.1038/s41592-018-0051-x. Epub 2018 Jul 16.
9
Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression.旁分泌信号通过上调 PD-L1 表达抑制抗肿瘤免疫。
Cancer Res. 2018 Jul 15;78(14):3761-3768. doi: 10.1158/0008-5472.CAN-18-0040. Epub 2018 May 22.
10
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.纳武利尤单抗治疗晚期肝细胞癌患者(CheckMate 040):一项开放标签、非对照、1/2 期剂量递增和扩展试验。
Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.